Linked Life Data

17655683

Source:http://linkedlifedata.com/resource/pubmed/id/17655683

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2007-8-9
pubmed:abstractText
Treatment of erectile dysfunction (ED) has been greatly advanced by the advent of phosphodiesterase type-5 (PDE5) inhibitors. Upon the introduction of these agents, their cardiovascular (CV) safety was a major concern, mainly due to their vasodilatory effects. We conducted an electronic literature review of data concerning the safety and tolerability issues of men with ED receiving PDE5 inhibitors.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1368-5031
pubmed:author
pubmed:issnType
Print
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1547-54
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
pubmed:affiliation
Section of Andrology & Male Infertility, Department of Urology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA. whellst@tulane.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't